


**What is claimed is:**

1. A compound of formula (I):




wherein

- 10
- A is CH or N;  
X is F, Cl, or Br;  
Y is hydrogen, hydroxy, or (C<sub>1</sub>-C<sub>7</sub>)alkoxy; and  
Z is an amino acid, or heterocycle;  
or a pharmaceutically acceptable salt thereof.
- 15
2. The compound of claim 1, wherein Y is H.
3. The compound of claim 1, wherein Y is -OH.
4. The compound of claim 1, wherein Y is -OMe.
- 20
5. The compound of any of claims 1 to 4 wherein X is -Cl.
6. The compound of any of claims 1 to 4 wherein X is -Br.
- 25
7. The compound of any of claims 1 to 6 wherein Z is an amino acid.
8. The compound of any of claims 1 to 6 wherein Z is -NH-(CH<sub>2</sub>)<sub>2</sub>-SO<sub>3</sub>H.
9. The compound of any of claims 1 to 6 wherein Z is -NH-CH<sub>2</sub>-CO<sub>2</sub>H.
- 30
10. The compound of any of claims 1 to 6 wherein Z is -NH-CH(CH<sub>3</sub>)-CO<sub>2</sub>H.

11. The compound of any of claims 1 to 6 wherein Z is a nitrogen linked pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.

5

12. A compound of formula (I):



10

wherein

A is CH;

X is F, Cl, or Br;

Y is hydroxy, or (C<sub>1</sub>-C<sub>7</sub>)alkoxy; and

Z is an -NR<sub>a</sub>R<sub>b</sub>;

15

where R<sub>a</sub> and R<sub>b</sub> is independently hydrogen, (C<sub>1</sub>-C<sub>7</sub>)alkyl, (C<sub>1</sub>-C<sub>7</sub>)alkanoyl, aryl, aryl(C<sub>1</sub>-C<sub>7</sub>)alkyl, or where R<sub>a</sub> and R<sub>b</sub> together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

20

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 12, wherein Y is -OH.

14. The compound of claim 12, wherein Y is -OMe.

25

15. The compound of any of claims 12 to 14 wherein X is -Cl.


16. The compound of any of claims 12 to 14 wherein X is -Br.

30

17. The compound of any of claims 12 to 16 wherein Z is -NR<sub>a</sub>R<sub>b</sub>.

18. The compound of any of claims 12 to 16 wherein Z is -NH<sub>2</sub>.

19. The compound of any of claims 12 to 16 wherein Z is  $\text{-NHCH}_3$ .
20. The compound of any of claims 12 to 16 wherein Z is a nitrogen linked  
 5 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
21. A compound of formula (I):



10

wherein

A is CH;

X is F, Cl, or Br;

15 Y is hydrogen, hydroxy, or  $(\text{C}_1\text{-C}_7)$ alkoxy; and

Z is  $\text{-NR}_a\text{R}_b$ ; and 0


$\text{R}_a$  and  $\text{R}_b$  are each independently hydrogen,  $(\text{C}_1\text{-C}_7)$ alkyl,  
 $(\text{C}_1\text{-C}_7)$ alkanoyl, aryl, aryl $(\text{C}_1\text{-C}_7)$ alkyl, or where  $\text{R}_a$  and  $\text{R}_b$  together with  
 the nitrogen to which they are attached are a pyrrolidino, piperidino,  
 20 morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-  
 benzodiazepino;  
 or a pharmaceutically acceptable salt thereof.

22. The compound of claim 21 wherein  $\text{R}_a$  and  $\text{R}_b$  are each independently  
 25  $(\text{C}_1\text{-C}_7)$ alkanoyl, aryl, aryl $(\text{C}_1\text{-C}_7)$ alkyl, or where  $\text{R}_a$  and  $\text{R}_b$  together with  
 the nitrogen to which they are attached are a pyrrolidino, piperidino,  
 morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-  
 benzodiazepino.

30 23. The compound of claim 21 or 22 wherein Y is H.

24. The compound of claim 21 or 22 wherein Y is  $\text{-OH}$ .

25. The compound of claim 21 or 22 wherein Y is -OMe.
26. The compound of any of claims 21 to 25 wherein X is -Cl.
- 5 27. The compound of any of claims 21 to 25 wherein X is -Br.
28. The compound of any of claims 21 to 27 wherein Z is -NR<sub>a</sub>R<sub>b</sub>.
- 10 29. The compound of any of claims 21 to 27 wherein Z is a nitrogen linked pyrrolidino, piperidino, or morpholino.
30. The compound of any of claims 21 to 27 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 15 31. A compound of formula (I):



(I)

20

wherein

- A is N;
- X is F, Cl, or Br;
- Y is hydroxy; and
- 25 Z is an -NR<sub>a</sub>R<sub>b</sub>;

where R<sub>a</sub> and R<sub>b</sub> are each independently hydrogen, (C<sub>1</sub>-C<sub>7</sub>)alkyl, (C<sub>1</sub>-C<sub>7</sub>)alkanoyl, aryl, aryl(C<sub>1</sub>-C<sub>7</sub>)alkyl, or where R<sub>a</sub> and R<sub>b</sub> together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

30 or a pharmaceutically acceptable salt thereof.

32. The compound of claim 30 wherein where  $R_a$  and  $R_b$  are each independently hydrogen,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ alkanoyl, aryl, aryl $(C_1-C_7)$ alkyl, or where  $R_a$  and  $R_b$  together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino.

5

33. The compound of claim 31 or 32 wherein X is  $-Cl$ .

34. The compound of claim 31 or 32 wherein X is  $-Br$ .

- 10 35. The compound of any of claims 31 to 34 wherein Z is  $-NR_aR_b$ .

36. The compound of any of claims 31 to 34 wherein Z is  $-NH_2$ .

37. The compound of any of claims 31 to 34 wherein Z is  $-NHCH_3$ .

15

38. The compound of any of claims 31 to 34 wherein Z is  $-N(CH_3)_2$ .


39. The compound of any of claims 31 to 34 wherein Z is a nitrogen linked pyrrolidino, piperidino, or morpholino.

20

40. The compound of any of claims 31 to 34 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.

41. A compound of formula (I):

25



(I)

wherein

30

A is N;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or  $(C_1-C_7)$ alkoxy; and

Z is -NR<sub>a</sub>R<sub>b</sub>;

where R<sub>a</sub> and R<sub>b</sub> are independently (C<sub>1</sub>-C<sub>7</sub>)alkanoyl, aryl, aryl(C<sub>1</sub>-C<sub>7</sub>)alkyl, or where R<sub>a</sub> and R<sub>b</sub> together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;  
or a pharmaceutically acceptable salt thereof.

42. The compound of claim 41 wherein Y is H.
43. The compound of claim 41 wherein Y is -OH.
44. The compound of claim 41 wherein Y is -OMe.
45. The compound of any of claims 41 to 44 wherein X is -Cl.
46. The compound of any of claims 41 to 44 wherein X is -Br.
47. The compound of any of claims 41 to 46 wherein R<sub>a</sub> and R<sub>b</sub> are independently (C<sub>1</sub>-C<sub>7</sub>)alkanoyl, aryl, or aryl(C<sub>1</sub>-C<sub>7</sub>)alkyl.
48. The compound of any of claims 41 to 46 wherein R<sub>a</sub> and R<sub>b</sub> together with the nitrogen to which they are attached are pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
49. The compound  
2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy} propionmethylamide;  
2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy} propiondimethylamide;  
(2-(4-(7-Chloro-2-quinoxalinyloxy)phenoxy) propionylamino ethane-  
sulfonic acid;  
(2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino ethane-  
sulfonic acid;  
{2-{4-(7-Bromo-quinolin-2-yloxy)phenoxy} propionylamino} acetic acid;

- {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy} propionyl amino}  
acetic acid;  
(R) (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino  
ethanesulfonic acid;  
5 (R) {2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino}  
acetic acid; and  
(R) {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy} propionyl amino}  
acetic acid;  
or pharmaceutically acceptable salts thereof.
- 10
50. The compound of any of claims 1 to 49 which is the (R) enantiomer.
51. The compound of any of claims 1 to 49 which is the (S) enantiomer.
- 15 52. The compound of any of claims 1 to 51, wherein the compound is  
isolated and purified.
53. The compound of claim 52, wherein the compound is a solid.
- 20 54. The compound of claim 52, wherein the compound is a crystalline solid.
55. A pharmaceutical composition comprising a compound any one of claims  
1 to 54 and a pharmaceutically acceptable diluent or carrier.
- 25 56. The pharmaceutical composition of claim 55, wherein the pharmaceutical  
composition is formulated as a unit dosage form.
57. The pharmaceutical composition of claim 56, wherein the unit dosage  
form is formulated for oral administration.
- 30 58. The pharmaceutical composition of claim 56, wherein the unit dosage  
form is formulated for administration by injection.
59. The compound of any one of claims 1 to 54 for use in medical therapy.

60. The use of a compound of any one of claims 1 to 54 for the manufacture of a medicament for the treatment of cancer in a mammal.
- 5 61. A therapeutic method to treat cancer in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a compound of of any one of claims 1 to 54.
- 10 62. A therapeutic method to treat cancer in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a pharmaceutical composition of of any one of claims 55 to 58.
- 15 63. A therapeutic method to treat cancer in a mammal, comprising co-administering to a mammal in need of such therapy, an effective amount of a mixture of two or more compounds of any one of claims 1 to 54.
- 20 64. A therapeutic method to treat cancer in a mammal, comprising co-administering to a mammal in need of such therapy, an effective amount of a mixture of two or more pharmaceutical compositions of any one of claims 55 to 58.